SCHEMBL29560969

SCHEMBL29560969

CC(C)Nc1nc(Nc2ccncc2F)nc(-c2ccccc2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH3 Q9ULD8 9/20 0.50
NPC1 O15118 1/20 0.49
TSHR P16473 1/20 0.49
HSD17B10 Q99714 1/20 0.49
IDH1 O75874 1/20 0.43
CTSK P43235 1/20 0.42
IDH2 P48735 1/20 0.41
LATS1 O95835 2/20 0.40
ABL1 P00519 1/20 0.40
LCK P06239 1/20 0.40
CSF1R P07333 1/20 0.40
PDGFRB P09619 1/20 0.40
MAP2K2 P36507 1/20 0.40
CDK7 P50613 1/20 0.40
POLB P06746 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
MEN1 O00255 1/20 0.39
CLK1 P49759 1/20 0.39
KMT2A Q03164 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15094951 1.00 KCNH3 (0.50) KCNH3NPC1TSHRHSD17B10IDH1
SCHEMBL15102609 0.86 KCNH3 (0.50) KCNH3NPC1TSHRHSD17B10IDH1
SCHEMBL29560280 0.86 KCNH3 (0.50) KCNH3NPC1TSHRHSD17B10IDH1
SCHEMBL18520669 0.85 KCNH3 (0.47) KCNH3NPC1TSHRHSD17B10IDH1
SCHEMBL15094829 0.82 CTSK (0.51) KCNH3NPC1TSHRHSD17B10IDH1
SCHEMBL16391702 0.82 ABCG2 (0.52) NPC1TSHRHSD17B10LATS1ABL1
SCHEMBL29561752 0.82 KCNH3 (0.67) KCNH3NPC1TSHRHSD17B10IDH1
SCHEMBL15102579 0.82 KCNH3 (0.67) KCNH3NPC1TSHRHSD17B10IDH1
SCHEMBL15102560 0.81 KCNH3 (0.53) KCNH3NPC1TSHRHSD17B10IDH1
SCHEMBL16388175 0.81 NPSR1 (0.48) KCNH3NPC1HSD17B10IDH2LATS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4647076-A2 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE Les Laboratoires Servier (FR) 2025-11-12 EP disclosed
EP-3984997-B1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER LAB (FR) 2025-07-30 EP disclosed
US-20230250078-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC (US) 2023-08-10 US disclosed
US-11505538-B1 Therapeutically active compounds and their methods of use SERVIER PHARMACEUTICALS LLC (US) 2022-11-22 US disclosed
US-20220348554-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2022-11-03 US disclosed
CN-108912066-B Therapeutically active compounds and methods of use thereof 安吉奥斯医药品有限公司 2022-06-24 CN disclosed
EP-3984997-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE Les Laboratoires Servier SAS (FR) 2022-04-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348554-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE MCL1, TP53, BRDT KCNH3 4722/4885NPC1 513/4885TSHR 3788/4885
US-20230250078-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE MCL1, TP53, BRDT KCNH3 4722/4885NPC1 513/4885TSHR 3788/4885
US-11505538-B1 Therapeutically active compounds and their methods of use MCL1, TP53, BRDT KCNH3 4722/4885NPC1 513/4885TSHR 3788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.